阿托品联合其他干预措施在近视防控中的研究进展  

Research progress of atropine combined with other interventions in the prevention and control of myopia

作　　者：张毅[1] 崔亚晨 闫瑾[1] 李树茂[1] ZHANG Yi;CUI Ya-chen;YAN Jin(Tianjin Eye Hospital,Tianjin 300041,China)

机构地区：[1]天津市眼科医院,300041

出　　处：《中国现代药物应用》2024年第1期172-174,共3页Chinese Journal of Modern Drug Application

摘　　要：本文综述了近视的发生发展机制和对应的治疗策略,重点阐述了应用阿托品联合其他干预措施治疗近视的作用机制及研究进展,并通过比较各种治疗方法的优缺点,提供更安全、有效的治疗方案,以便更好地推动近视治疗的发展。This paper reviews the occurrence and development mechanism of myopia and corresponding treatment strategies,focuses on the mechanism of action and research progress of the application of atropine combined with other intervention measures in the treatment of myopia,and provides a safer and more effective treatment plan by comparing the advantages and disadvantages of various treatment methods,so as to better promote the development of myopia treatment.

关 键 词：低浓度阿托品 联合干预 近视 

分 类 号：R778.11[医药卫生—眼科]